Morocco's Pursuit of Affordable Medication: A Continuing Trend
Morocco is persisting in its efforts to make essential medications more accessible by continuously revising and reducing their prices. This initiative is being carried out through successive amendments to Decision No. 787.14, which was first issued in April 2014 and pertains to the public sale prices of original, generic, and biosimilar drugs marketed within the country.
The Ministry of Health has recently unveiled a new list of medications that will see price reductions, following a previous decision that focused on cancer and liver treatments. This latest update, published in the most recent issue of the official bulletin, is outlined in Ministerial Decision No. 1717.24. The decision encompasses price revisions and reductions for both hospital and public sales, affecting the pricing of 16 drugs and granting marketing approval for seven additional medications.
Among the notable price reductions is FLUCONAZOLE AGUETTANT (2 mg), an antifungal medication used to treat conditions such as meningitis, coccidioidomycosis, and mucosal fungal infections. The price has been lowered to MAD472, down from MAD810.
TAZOCILLINE (4 mg), utilized for treating pneumonia, abdominal infections, and urinary tract infections, has seen its public sale price reduced to MAD203 from MAD239, while its hospital sale price has been lowered to MAD127 from MAD149.
Trinomyc (2 mg), another medication for infections, has had its public sale price reduced to MAD62 from MAD134, and its hospital sale price lowered to MAD39 from MAD84.
This ongoing endeavor by the Moroccan Ministry of Health underscores a commitment to enhancing the affordability and accessibility of crucial medications, thereby improving public health outcomes across the nation.